Department of Thoracic Surgery, Qilu Hospital, Shandong University, Wen hua xi lu 107#, Jinan 250012, Shandong, China.
World J Surg. 2012 Mar;36(3):623-31. doi: 10.1007/s00268-011-1421-z.
The purposes of the present study were to detect the expression of metastasis-associated protein 1 (MTA1) in patients with esophageal squamous cell cancer (ESCC), and to evaluate the relevance of MTA1 protein expression to the tumor progression, angiogenesis, and prognosis.
Both MTA1 protein and intratumoral microvessels were examined by immunohistochemical staining in 131 ESCC patients who successfully underwent subtotal esophagectomy and esophagogastric anastomosis at Qilu Hospital between Jan 2004 and Dec 2005. Intratumoral microvessel density (MVD) was recorded by counting CD-34 positive immunostained endothelial cells. All statistical analyses were performed with SPSS 13.0 statistical software.
High expression of MTA1 protein was detected in 57 cases and significantly correlated with tumor invasion depth (P = 0.041), lymph node metastasis (P = 0.021), pathologic stage (P = 0.003), and MVD (P = 0.044). Survival analysis showed that patients with MTA1 protein high expression had significantly poor overall 5-year survival (P = 0.002), and the factor found on multivariate analysis to significantly affect overall survival was only pathologic stage (P = 0.040). Further stratified survival analysis split by pathologic stage demonstrated that MTA1 protein high expression significantly predicted unfavorable prognosis among patients with pathologic stage II disease (P = 0.006).
High expression of the MTA1 protein is common in ESCC, and is closely associated with tumor progression, increased tumor angiogenesis, and poor survival. These findings indicate that MTA1 protein has clinical potentials as a useful indicator of progressive phenotype, a promising prognostic predictor to identify patients with poor prognosis, and a potential novel therapeutic target of antiangiogenesis for patients with ESCC.
本研究旨在检测食管鳞癌（ESCC）患者中转移相关蛋白 1（MTA1）的表达，并评估 MTA1 蛋白表达与肿瘤进展、血管生成和预后的相关性。
2004 年 1 月至 2005 年 12 月，齐鲁医院对 131 例成功接受食管次全切除和胃食管吻合术的 ESCC 患者进行了 MTA1 蛋白和肿瘤内微血管检测，采用免疫组化染色法。通过计数 CD-34 阳性免疫染色的内皮细胞来记录肿瘤内微血管密度（MVD）。所有统计分析均采用 SPSS 13.0 统计软件进行。
高表达 MTA1 蛋白 57 例，与肿瘤浸润深度（P = 0.041）、淋巴结转移（P = 0.021）、病理分期（P = 0.003）和 MVD（P = 0.044）显著相关。生存分析显示，MTA1 蛋白高表达患者总 5 年生存率显著降低（P = 0.002），多因素分析显示，影响总生存率的唯一因素是病理分期（P = 0.040）。进一步按病理分期分层生存分析显示，MTA1 蛋白高表达显著预测 II 期患者预后不良（P = 0.006）。
MTA1 蛋白在 ESCC 中表达较高，与肿瘤进展、肿瘤血管生成增加和生存不良密切相关。这些发现表明，MTA1 蛋白具有作为进展表型的有用指标、预测预后不良的有前途的预测因子以及 ESCC 患者抗血管生成治疗的潜在新治疗靶点的临床潜力。
